Senseonics Holdings Inc. (SENS) Gains "Buy" Rating with Strong Growth Forecast

Senseonics Holdings Inc (SENS) has been assigned a "Buy" rating by analyst Ben Haynor and a price target of $1. The company projects to serve 12,000 patients by the end of 2023, doubling to 24,000 by 2024, and exceeding 50,000 by 2027. The average target price for SENS is $1.55, with an average brokerage recommendation of 2.6, indicating a "Hold" status. Net revenue for Q1 2025 increased by 24% to $6.3 million.

Senseonics Holdings Inc (SENS) has received a positive "Buy" rating from analyst Ben Haynor of Lake Street, with a price target of $1.00. The company projects to serve 12,000 patients by the end of 2023, doubling to 24,000 by 2024, and exceeding 50,000 by 2027. The average target price for SENS is $1.55, with an average brokerage recommendation of 2.6, indicating a "Hold" status. Net revenue for Q1 2025 increased by 24% to $6.3 million [1].

The analyst's positive outlook is supported by Senseonics' groundbreaking work in implantable continuous glucose monitors, particularly the Eversense 365, the only implantable continuous glucose monitor available. The company has set ambitious user growth expectations, projecting to serve 12,000 patients by the end of this year, doubling that number to 24,000 by next year, and exceeding 50,000 by 2027 [1].

Wall Street analysts have forecasted an average target price of $1.55 for SENS, with a high estimate of $2.00 and a low estimate of $1.25. The average target implies an upside of 188.96% from the current price of $0.54. The average brokerage recommendation is currently 2.6, indicating a "Hold" status [1].

Senseonics reported a 24% increase in net revenue for Q1 2025, reaching $6.3 million compared to $5 million in the prior year. The company also announced the integration of its EverSense 365 continuous glucose monitor with SQL's Twist Automated Insulin Delivery System, enhancing patient experience through simplified insulin delivery [1].

Senseonics has filed for CE mark approval for EverSense 365, with a European launch expected in the second half of 2025. The company has successfully transitioned many US payers to reimburse EverSense 365 for a full year, with Medicare updating its physician fee schedule to support this change [1].

Senseonics will announce its Q2 2025 financial results on August 6, followed by a conference call. The company specializes in developing long-term, implantable continuous glucose monitoring (CGM) systems for diabetes management. Its products include Eversense® 365 and Eversense® E3, implantable glucose monitoring systems [2].

References:
[1] https://www.gurufocus.com/news/2984030/senseonics-sens-gains-buy-rating-and-strong-growth-forecast-sens-stock-news
[2] https://www.nasdaq.com/articles/senseonics-holdings-inc-announce-second-quarter-2025-financial-results-august-6-2025